Ninlaro Positive In Non-Transplant MM Maintenance
Results To Pave Way For 'Bundled' Submission?
Executive Summary
Following a failure in a different indication earlier this year, positive top-line results show promise for Takeda proteasome inhibitor positive in first-line myeloma maintenance in non-transplant patients, setting the path for approval filings.
You may also be interested in...
Takeda’s Ninlaro Misses Mark In Transplant-Ineligible 1L Myeloma
Oral proteasome inhibitor fails to reach significance when added to standard combination therapy in first-line myeloma patients who cannot receive marrow transplants, but development continues in other settings.
Ninlaro Failure Leaves Little In AL Amyloidosis Pipeline
Takeda proteasome inhibitor stumbles at Phase III among potential first therapies for a deadly form of amyloidosis.
Ninlaro Looking Positive In MM Maintenance On Back Of TOURMALINE Data
Takeda's Ninlaro seems to have proved its mettle in the first major placebo-controlled trial assessing a proteasome inhibitor as a single-agent maintenance therapy in multiple myeloma.